title: Low-dose subcutaneous erythropoietin in continuous ambulatory peritoneal dialysis.
abstract: We evaluated changes in hematocrit in patients on continuous ambulatory peritoneal dialysis (CAPD) before and after the administration of erythropoietin (EPO). Thirty-five patients were evaluated at the beginning of treatment with CAPD and after an average of 3.5 years on CAPD; mean hematocrit (Hct) rose from 25.4 +/- 5.4% to 28.1 +/- 6.7% (P less than 0.001). In the period before EPO administration 11 patients required a total of 44 transfusions (one patient needed 23 transfusions). Fifteen patients were started on subcutaneous erythropoietin 3,000 units 3 times a week and were followed for a mean period of 6.3 months. Hct rose from 23.8 +/- 1.8% to 25.2 +/- 2.4% (P less than 0.01) within the first 2 weeks and up to 27.5 +/- 3.7% (P less than 0.01) in the fourth week. By the eighth week the target Hct (30 to 35%) was reached. During the next 5 months the EPO doses were adjusted to each patient's needs ranging between 2,000 U per week to 4,000 U 3 times per week. Mild hypertension was the only side effect seen in some of the patients. In conclusion low dose subcutaneous EPO is effective in managing the anemia of patients on CAPD with only minor side effects.
authors.affiliation: Georgetown University Medical Center, Washington, DC 20007.
authors.forename: C
authors.initials: C
authors.lastname: Rotellar
authors.forename: M J
authors.initials: MJ
authors.lastname: Mazzoni
authors.forename: W F
authors.initials: WF
authors.lastname: Mosher
authors.forename: M
authors.initials: M
authors.lastname: Aminrazavi
authors.forename: A
authors.initials: A
authors.lastname: Bauer
authors.forename: T A
authors.initials: TA
authors.lastname: Rakowski
authors.forename: G E
authors.initials: GE
authors.lastname: Schreiner
authors.forename: J F
authors.initials: JF
authors.lastname: Winchester
mesh_terms: D000328:Adult; D000368:Aged; D000740:Anemia / Q000188:drug therapy; D003401:Creatine / Q000097:blood; D004305:Dose-Response Relationship, Drug; D004921:Erythropoietin / Q000008:administration & dosage* / Q000627:therapeutic use; D005260:Female; D006400:Hematocrit; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D010531:Peritoneal Dialysis, Continuous Ambulatory; D010710:Phosphates / Q000097:blood; D011188:Potassium / Q000097:blood
chemical_list: D010710:Phosphates; D004921:Erythropoietin; D003401:Creatine; D011188:Potassium